Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: gogerly moragoda m. Nat Med. 2024 Apr;30(4):1211. doi: 10.1038/s41591-024-02814-0. Nat Med. 2024. PMID: 38242983 Free PMC article. No abstract available.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: gogerly moragoda m. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.
Qin Q, Jun T, Wang B, Patel VG, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh AB, Leiter A, Gallagher EJ, Alerasool P, Garcia P, Joshi H, Mbbs, Galsky M, Oh WK, Tsao CK. Qin Q, et al. Among authors: gogerly moragoda m. Discov Oncol. 2022 Aug 12;13(1):73. doi: 10.1007/s12672-022-00538-6. Discov Oncol. 2022. PMID: 35960456 Free PMC article.
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Mellgard G, Patel VG, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher EJ, Oh WK, Galsky MD, Tsao CK. Mellgard G, et al. Among authors: gogerly moragoda m. J Cancer Res Clin Oncol. 2023 Jul;149(7):2833-2841. doi: 10.1007/s00432-022-04159-y. Epub 2022 Jul 5. J Cancer Res Clin Oncol. 2023. PMID: 35788726